Tectonic Therapeutic Inc/$TECX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Tectonic Therapeutic Inc

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Ticker

$TECX
Sector
Health
Primary listing
NASDAQ

Employees

51
Headquarters
Watertown, United States
Website
tectonictx.com

TECX Metrics

BasicAdvanced
$305M
-
-$4.03
-
-

Bulls say / Bears say

Phase 1b results as of May 17, 2025 showed TX45 was well tolerated, with no serious adverse events, and produced a 19% decrease in PCWP, over 30% reduction in PVR, and sustained hemodynamic effects for 29 days in PH-HFpEF patients. (GlobeNewswire)
As of June 30, 2025, Tectonic reported $287.4 million in cash and cash equivalents, strengthened by net proceeds from a February 2025 private placement. Management expects this will fund operations into Q4 2028. (GlobeNewswire)
On March 21, 2025, Wells Fargo reaffirmed an overweight rating on Tectonic, setting a price objective of $101, reflecting ongoing institutional confidence in the company’s GPCR-focused pipeline. (InsiderTrades)
For Q4 2024, Tectonic reported a net loss of $12.4 million, mainly due to $9.2 million in R&D expenses and $4.8 million in G&A expenses. This highlights a high cash burn and the absence of product revenues. (GlobeNewswire)
The company’s second pipeline candidate, TX2100 for HHT, remains in preclinical development with Phase 1 trials not anticipated until Q4 2025 or Q1 2026, delaying key catalyst events. (GlobeNewswire)
Interim Phase 1b data released on January 30, 2025 prompted a 45% pre-market jump in the stock, highlighting notable volatility and binary event risk for investors as they wait for future trial results. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TECX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs